The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents
Open accessAbstract
Some, but not all, antiresorptive agents have been shown to reduce the risk of nonvertebral fractures. Agents that significantly reduced nonvertebral fracture risk also appear to produce larger mean increases in bone mineral density (BMD) and reductions in biochemical markers (BCM) of bone turnover, compared with other agents. To examine the extent to which increases in BMD and reductions in BCM during antiresorptive therapy are associated with reductions in risk of nonvertebral fractures, we performed a meta-analysis of all randomized, placebo-controlled trials of antiresorptive agents conducted in postmenopausal women with osteoporosis (i.e. prior vertebral fracture or low BMD) with available relevant data. A total of 18 such trials with usable data were identified, including a total of 2,415 women with incident nonvertebral fractures over 69,369 women-years of follow-up. Poisson regression was used to estimate the association between changes in BMD or BCM during the first year and overall reductions in risk of nonvertebral fractures (vs. the placebo group) across all trials. Larger increases in BMD and larger reductions in BCM were significantly associated with greater reductions in nonvertebral fracture risk. For example, each 1% increase in spine BMD at 1 yr was associated with an 8% reduction in nonvertebral fracture risk (P = 0.02). Mean BMD changes at the hip were smaller than at the spine, but the predicted net effect on fracture risk was the same; an agent that increases spine BMD by 6% at 1 yr reduces nonvertebral fracture risk by about 39%, and an agent that increases hip BMD by 3% at 1 yr reduces nonvertebral fracture risk by about 46%. The results also predict that a 70% reduction in resorption BCM would reduce risk by 40%, and a 50% reduction in formation BCM would reduce risk by 44%. It appears that either BMD or BCM changes are able to explain the effect of treatment, because a separate variable for treatment was not independently significant in any models. These data demonstrate that larger increases in BMD at both the spine and hip and larger reductions in both formation and resorption BCM are associated with greater reductions in the risk of nonvertebral fractures. Antiresorptive agents that do not produce large increases in BMD or large reductions in BCM do not appear to and would not be expected to decrease the risk of nonvertebral fractures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis
(1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90218-e · Cited by 2,874
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Self-citation
Cited by
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Self-citationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., Burlet, N., Cooper, C., Delmas, P. D., Reginster, J.-Y., Borgstrom, F., Rizzoli, R., & on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 776
Bone strength and its determinants
Ammann, P., & Rizzoli, R. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1345-4 · Cited by 761
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 478
Kendler, D. L., Roux, C., Benhamou, C. L., Brown, J. P., Lillestol, M., Siddhanti, S., Man, H.-S., Martin, J. S., & Bone, H. G. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090716 · Cited by 453
Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper, M., Luckey, M. M., McClung, M. R., Pollack, R. P., et al. (2010) · Endocrine Practice · doi:10.4158/ep.16.s3.1 · Cited by 441
Bauer, D. C., Black, D. M., Garnero, P., Hochberg, M., Ott, S., Orloff, J., Thompson, D. E., Ewing, S. K., Delmas, P. D., & for the Fracture Intervention Trial Study Group (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040512 · Cited by 405
Self-citationThe Assessment of Fracture Risk
Unnanuntana, A., Gladnick, B. P., Donnelly, E., & Lane, J. M. (2010) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/jbjs.i.00919 · Cited by 361
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Bouxsein, M. L., Eastell, R., Lui, L.-Y., Wu, L. A., de Papp, A. E., Grauer, A., Marin, F., Cauley, J. A., Bauer, D. C., Black, D. M., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3641 · Cited by 353
Rosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040920 · Cited by 345
Self-citationPapapoulos, S., Chapurlat, R., Libanati, C., Brandi, M. L., Brown, J. P., Czerwiński, E., Krieg, M.-A., Man, Z., Mellström, D., Radominski, S. C., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1479 · Cited by 344
Recker, R., Lappe, J., Davies, K. M., & Heaney, R. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040710 · Cited by 343
Miller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
Self-citationReginster, J.-Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J. J., Silverman, S. L., Christiansen, C., Rowell, L., Mairon, N., Bonvoisin, B., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044958 · Cited by 326
Self-citationDXA scanning in clinical practice
El Maghraoui, A., & Roux, C. (2008) · QJM · doi:10.1093/qjmed/hcn022 · Cited by 323
Heaney, R. P. (2003) · Bone · doi:10.1016/s8756-3282(03)00236-9 · Cited by 306
Delmas, P. D., & Seeman, E. (2004) · Bone · doi:10.1016/j.bone.2003.12.022 · Cited by 294
Ensrud, K. E., Barrett-Connor, E. L., Schwartz, A., Santora, A. C., Bauer, D. C., Suryawanshi, S., Feldstein, A., Haskell, W. L., Hochberg, M. C., Torner, J. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040326 · Cited by 275
Self-citationBolotin, H. H. (2007) · Bone · doi:10.1016/j.bone.2007.02.022 · Cited by 274
“[60] to relate in vivo (BMD)DXA measurements to the incidence of new vertebral and non-vertebral fracture occurrences during treatment with anti-resorptive agents.”
BackgroundRauchenzauner, M., Schmid, A., Heinz-Erian, P., Kapelari, K., Falkensammer, G., Griesmacher, A., Finkenstedt, G., & Högler, W. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1706 · Cited by 272
Bone turnover markers: use in osteoporosis
Naylor, K., & Eastell, R. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.86 · Cited by 262
(2008) · PubMed · Cited by 160
Zein, C. O., Jorgensen, R. A., Clarke, B., Wenger, D. E., Keach, J. C., Angulo, P., & Lindor, K. D. (2005) · Hepatology · doi:10.1002/hep.20866 · Cited by 142
Van Caenegem, E., Wierckx, K., Taes, Y., Schreiner, T., Vandewalle, S., Toye, K., Kaufman, J.-M., & T’Sjoen, G. (2015) · Osteoporosis International · doi:10.1007/s00198-014-2805-3 · Cited by 116
The effects of organic nitrates on osteoporosis: A systematic review
Jamal, S. A., Reid, L. S., & Hamilton, C. J. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2262-9 · Cited by 27
Combination therapy of raloxifene and alendronate for treatment of osteoporosis in elderly women
Um, M. J., Cho, E. A., & Jung, H. (2017) · Journal of Menopausal Medicine · doi:10.6118/jmm.2017.23.1.56 · Cited by 14
Metadata
- Authors
- Hochberg, M. C.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-04-01
- Volume
- 87
- Issue
- 4
- Pages
- 1586-1592
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W1987169166
- Cited by
- 480
- References
- 42
- FWCI
- 33.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.